David Young, DO
Pulmonary Disease · Wyomissing, PANPI 1285954321
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.6%), education and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Intuitive Surgical at 47.6% of the total. Reporting peaked in 2022 at $4,629 and has fallen 76.4% since, to $1,090 in 2025.
Across 198 payments — averaging $42.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$701
- AstraZeneca$505
- Sanofi$350
- Regeneron Healthcare Solutions, Inc.$324
- Insmed, Inc.$246
- plus $2K from 31 others
Across 3 payments — averaging $1328.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$4K
What the payments were for
- Travel & lodging$96111%
- Food & beverage$4,39953%
- Education$3,00036%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $3,978 |
| GSK | 39 | $701 |
| AstraZeneca | 19 | $505 |
| Sanofi | 17 | $350 |
| Regeneron Healthcare Solutions, Inc. | 13 | $324 |
| Insmed, Inc. | 13 | $246 |
| Mylan Specialty L.p. | 11 | $235 |
| Inari Medical, Inc. | 2 | $198 |
| Boston Scientific | 2 | $195 |
| Harmony Biosciences LLC | 6 | $163 |
| Pulmonx Corporation | 2 | $148 |
| Axsome Therapeutics, Inc. | 8 | $133 |
| Boehringer Ingelheim | 8 | $133 |
| Merck | 8 | $127 |
| United Therapeutics Corporation | 5 | $107 |
| Grifols USA, LLC | 3 | $89 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $70 |
| ANI Pharmaceuticals, Inc. | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 2 | $62 |
| Genentech USA, Inc. | 3 | $55 |
| Verona Pharma, Inc. | 2 | $53 |
| Vifor Pharma, Inc. | 3 | $51 |
| Ambu Inc. | 1 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $36 |
| Viatris Specialty LLC | 1 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $32 |
| Shire North American Group Inc | 2 | $30 |
| 3b Medical, Inc. | 2 | $25 |
| Amgen | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Novartis | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$942
- FLOWTRIEVER CATHETER, S$180
- CT THROMBECTOMY SYSTEM KIT$180
- CHARTIS CATHETER$130
- ZEPHYR DELIVERY CATHETER$130
- ZEPHYR ENDOBRONCHIAL VALVE$130
- PULMONX CHARTIS TABLET CONSOLE$130
- TEZSPIRE$115
- BREZTRI$113
- FASENRA$113
- COREDX$101
How this compares
$8,360 in reported general payments places this provider in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $245,880 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 195 | $223,126 |
| EsbrietPirfenidone | 11 | $114,062 |
| Breo ElliptaFluticasone/Vilanterol | 130 | $80,901 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 64 | $50,589 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $49,140 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $43,617 |
| Spiriva RespimatTiotropium Bromide | 33 | $32,780 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $21,106 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $16,477 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $12,359 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 206 | $6,588 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $6,407 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $6,325 |
| Varenicline Tartrate | 35 | $6,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $701 | $359,492402 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $133 | $329,249116 claims |
| Genentech USA, Inc.Esbriet | $55 | $114,06211 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $505 | $64,722102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Wyomissing
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.